Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study

Luis Rivera, Tino F. Schwarz, Kyung Hyo Kim, Yun Kyung Kim, Ulrich Behre, Sung Ho Cha, Dae Sun Jo, Jacob Lee, Jin Soo Lee, Brigitte Cheuvart, Archana Jastorff, Marie Van der Wielen

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: This study evaluated the immunogenicity and safety of quadrivalent meningococcal conjugate vaccine using tetanus (T) toxoid as carrier protein (MenACWY-TT) co-administered with combined diphtheria-tetanus-acellular pertussis vaccine (Tdap) versus their separate administration in adolescents and young adults. Methods: In this phase III, randomized, partially-blind study (NCT01767376), healthy 11–25-year-olds (N = 660) were randomized (1:1:1) to receive MenACWY-TT and Tdap at Month 0 (Co-ad group), MenACWY-TT at Month 0 and Tdap at Month 1 (ACWY_Tdap group) or Tdap at Month 0 and MenACWY-TT at Month 1 (Tdap_ACWY group). Immune responses to MenACWY-TT were measured by serum bactericidal assay using rabbit complement (rSBA). Anti-diphtheria (D), anti-tetanus (T), anti-pertussis toxin (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibody concentrations were assessed using enzyme-linked immunosorbent assays. Non-inferiority of immunogenicity was assessed using pre-defined clinical criteria. Safety was also evaluated. Results: Non-inferiority of immunogenicity of MenACWY-TT and Tdap when co-administered versus their separate administration was demonstrated in terms of rSBA geometric mean titers (GMTs) for 4 meningococcal serogroups and of the percentage of participants with antibody concentrations >1 IU/ml for D and T. Among the pertussis antigens, non-inferiority criteria for geometric mean concentrations (GMCs) were reached for PT, but not met for FHA and PRN. Across all groups, ≥93.2% of participants had vaccine responses to each meningococcal serogroup, ≥99.1% were seroprotected against T and D, and ≥85.5% had booster responses to each pertussis antigen. Robust increases in antibody GMTs/GMCs were observed for all antigens between pre-and post-vaccination. Both vaccines had clinically acceptable safety profiles. Conclusion: Immune responses to MenACWY-TT and to the T and D antigens from Tdap were not impacted by their co-administration. The lower antibody concentrations observed against the pertussis components may be of limited clinical relevance since robust anti-pertussis booster responses were observed. This study supports concurrent administration of the 2 vaccines in adolescents.

Original languageEnglish
Pages (from-to)4750-4758
Number of pages9
JournalVaccine
Volume36
Issue number31
DOIs
Publication statusPublished - 2018 Jul 25

Fingerprint

Diphtheria-Tetanus-acellular Pertussis Vaccines
Meningococcal Vaccines
Combined Vaccines
whooping cough
tetanus
young adults
Young Adult
immune response
vaccines
Whooping Cough
Safety
antigens
pertussis toxin
antibodies
hemagglutinins
Vaccines
serotypes
Pertussis Toxin
Hemagglutinins
Antigens

Keywords

  • Co-administration
  • Combined diphtheria-tetanus-acellular pertussis vaccine
  • Immunogenicity
  • Quadrivalent meningococcal conjugate vaccine
  • Safety

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults : A phase III, randomized study. / Rivera, Luis; Schwarz, Tino F.; Kim, Kyung Hyo; Kim, Yun Kyung; Behre, Ulrich; Cha, Sung Ho; Jo, Dae Sun; Lee, Jacob; Lee, Jin Soo; Cheuvart, Brigitte; Jastorff, Archana; Van der Wielen, Marie.

In: Vaccine, Vol. 36, No. 31, 25.07.2018, p. 4750-4758.

Research output: Contribution to journalArticle

Rivera, Luis ; Schwarz, Tino F. ; Kim, Kyung Hyo ; Kim, Yun Kyung ; Behre, Ulrich ; Cha, Sung Ho ; Jo, Dae Sun ; Lee, Jacob ; Lee, Jin Soo ; Cheuvart, Brigitte ; Jastorff, Archana ; Van der Wielen, Marie. / Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults : A phase III, randomized study. In: Vaccine. 2018 ; Vol. 36, No. 31. pp. 4750-4758.
@article{1fdc36eec24d42a8a9796111471f49cb,
title = "Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study",
abstract = "Background: This study evaluated the immunogenicity and safety of quadrivalent meningococcal conjugate vaccine using tetanus (T) toxoid as carrier protein (MenACWY-TT) co-administered with combined diphtheria-tetanus-acellular pertussis vaccine (Tdap) versus their separate administration in adolescents and young adults. Methods: In this phase III, randomized, partially-blind study (NCT01767376), healthy 11–25-year-olds (N = 660) were randomized (1:1:1) to receive MenACWY-TT and Tdap at Month 0 (Co-ad group), MenACWY-TT at Month 0 and Tdap at Month 1 (ACWY_Tdap group) or Tdap at Month 0 and MenACWY-TT at Month 1 (Tdap_ACWY group). Immune responses to MenACWY-TT were measured by serum bactericidal assay using rabbit complement (rSBA). Anti-diphtheria (D), anti-tetanus (T), anti-pertussis toxin (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibody concentrations were assessed using enzyme-linked immunosorbent assays. Non-inferiority of immunogenicity was assessed using pre-defined clinical criteria. Safety was also evaluated. Results: Non-inferiority of immunogenicity of MenACWY-TT and Tdap when co-administered versus their separate administration was demonstrated in terms of rSBA geometric mean titers (GMTs) for 4 meningococcal serogroups and of the percentage of participants with antibody concentrations >1 IU/ml for D and T. Among the pertussis antigens, non-inferiority criteria for geometric mean concentrations (GMCs) were reached for PT, but not met for FHA and PRN. Across all groups, ≥93.2{\%} of participants had vaccine responses to each meningococcal serogroup, ≥99.1{\%} were seroprotected against T and D, and ≥85.5{\%} had booster responses to each pertussis antigen. Robust increases in antibody GMTs/GMCs were observed for all antigens between pre-and post-vaccination. Both vaccines had clinically acceptable safety profiles. Conclusion: Immune responses to MenACWY-TT and to the T and D antigens from Tdap were not impacted by their co-administration. The lower antibody concentrations observed against the pertussis components may be of limited clinical relevance since robust anti-pertussis booster responses were observed. This study supports concurrent administration of the 2 vaccines in adolescents.",
keywords = "Co-administration, Combined diphtheria-tetanus-acellular pertussis vaccine, Immunogenicity, Quadrivalent meningococcal conjugate vaccine, Safety",
author = "Luis Rivera and Schwarz, {Tino F.} and Kim, {Kyung Hyo} and Kim, {Yun Kyung} and Ulrich Behre and Cha, {Sung Ho} and Jo, {Dae Sun} and Jacob Lee and Lee, {Jin Soo} and Brigitte Cheuvart and Archana Jastorff and {Van der Wielen}, Marie",
year = "2018",
month = "7",
day = "25",
doi = "10.1016/j.vaccine.2018.04.034",
language = "English",
volume = "36",
pages = "4750--4758",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "31",

}

TY - JOUR

T1 - Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults

T2 - A phase III, randomized study

AU - Rivera, Luis

AU - Schwarz, Tino F.

AU - Kim, Kyung Hyo

AU - Kim, Yun Kyung

AU - Behre, Ulrich

AU - Cha, Sung Ho

AU - Jo, Dae Sun

AU - Lee, Jacob

AU - Lee, Jin Soo

AU - Cheuvart, Brigitte

AU - Jastorff, Archana

AU - Van der Wielen, Marie

PY - 2018/7/25

Y1 - 2018/7/25

N2 - Background: This study evaluated the immunogenicity and safety of quadrivalent meningococcal conjugate vaccine using tetanus (T) toxoid as carrier protein (MenACWY-TT) co-administered with combined diphtheria-tetanus-acellular pertussis vaccine (Tdap) versus their separate administration in adolescents and young adults. Methods: In this phase III, randomized, partially-blind study (NCT01767376), healthy 11–25-year-olds (N = 660) were randomized (1:1:1) to receive MenACWY-TT and Tdap at Month 0 (Co-ad group), MenACWY-TT at Month 0 and Tdap at Month 1 (ACWY_Tdap group) or Tdap at Month 0 and MenACWY-TT at Month 1 (Tdap_ACWY group). Immune responses to MenACWY-TT were measured by serum bactericidal assay using rabbit complement (rSBA). Anti-diphtheria (D), anti-tetanus (T), anti-pertussis toxin (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibody concentrations were assessed using enzyme-linked immunosorbent assays. Non-inferiority of immunogenicity was assessed using pre-defined clinical criteria. Safety was also evaluated. Results: Non-inferiority of immunogenicity of MenACWY-TT and Tdap when co-administered versus their separate administration was demonstrated in terms of rSBA geometric mean titers (GMTs) for 4 meningococcal serogroups and of the percentage of participants with antibody concentrations >1 IU/ml for D and T. Among the pertussis antigens, non-inferiority criteria for geometric mean concentrations (GMCs) were reached for PT, but not met for FHA and PRN. Across all groups, ≥93.2% of participants had vaccine responses to each meningococcal serogroup, ≥99.1% were seroprotected against T and D, and ≥85.5% had booster responses to each pertussis antigen. Robust increases in antibody GMTs/GMCs were observed for all antigens between pre-and post-vaccination. Both vaccines had clinically acceptable safety profiles. Conclusion: Immune responses to MenACWY-TT and to the T and D antigens from Tdap were not impacted by their co-administration. The lower antibody concentrations observed against the pertussis components may be of limited clinical relevance since robust anti-pertussis booster responses were observed. This study supports concurrent administration of the 2 vaccines in adolescents.

AB - Background: This study evaluated the immunogenicity and safety of quadrivalent meningococcal conjugate vaccine using tetanus (T) toxoid as carrier protein (MenACWY-TT) co-administered with combined diphtheria-tetanus-acellular pertussis vaccine (Tdap) versus their separate administration in adolescents and young adults. Methods: In this phase III, randomized, partially-blind study (NCT01767376), healthy 11–25-year-olds (N = 660) were randomized (1:1:1) to receive MenACWY-TT and Tdap at Month 0 (Co-ad group), MenACWY-TT at Month 0 and Tdap at Month 1 (ACWY_Tdap group) or Tdap at Month 0 and MenACWY-TT at Month 1 (Tdap_ACWY group). Immune responses to MenACWY-TT were measured by serum bactericidal assay using rabbit complement (rSBA). Anti-diphtheria (D), anti-tetanus (T), anti-pertussis toxin (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibody concentrations were assessed using enzyme-linked immunosorbent assays. Non-inferiority of immunogenicity was assessed using pre-defined clinical criteria. Safety was also evaluated. Results: Non-inferiority of immunogenicity of MenACWY-TT and Tdap when co-administered versus their separate administration was demonstrated in terms of rSBA geometric mean titers (GMTs) for 4 meningococcal serogroups and of the percentage of participants with antibody concentrations >1 IU/ml for D and T. Among the pertussis antigens, non-inferiority criteria for geometric mean concentrations (GMCs) were reached for PT, but not met for FHA and PRN. Across all groups, ≥93.2% of participants had vaccine responses to each meningococcal serogroup, ≥99.1% were seroprotected against T and D, and ≥85.5% had booster responses to each pertussis antigen. Robust increases in antibody GMTs/GMCs were observed for all antigens between pre-and post-vaccination. Both vaccines had clinically acceptable safety profiles. Conclusion: Immune responses to MenACWY-TT and to the T and D antigens from Tdap were not impacted by their co-administration. The lower antibody concentrations observed against the pertussis components may be of limited clinical relevance since robust anti-pertussis booster responses were observed. This study supports concurrent administration of the 2 vaccines in adolescents.

KW - Co-administration

KW - Combined diphtheria-tetanus-acellular pertussis vaccine

KW - Immunogenicity

KW - Quadrivalent meningococcal conjugate vaccine

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=85048305823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048305823&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2018.04.034

DO - 10.1016/j.vaccine.2018.04.034

M3 - Article

C2 - 29960800

AN - SCOPUS:85048305823

VL - 36

SP - 4750

EP - 4758

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 31

ER -